RE:RE:RE:Where is Patient #4 6month results?No, not wrong. So far the market isn't showing any regard for no recurrence. Therefore we need a $10million sponsor to proceed with a Ph2.
Quattro74 wrote: This is wrong!
I dunno if patient #4 has seen recurrance, lets guess yes. That doesn't mean we need to see some of the remaining 5 go into remission. Efficacy = impact, we are 4/4 on halting progression, which is impact. Phase 1 study is about safety and tolerability, which TLT is also 4/4 on so far. If we have some remissions that is a big bonus to this phase 1. We just need safety/tolerability to continue a'pace. Phase 2 can be applied for and shouldnbe granted by FDA once TLT shows that it is safe. Now is that 90 days after #9 is treated or 180??
2b7f6fab wrote: Probably safe to assume #4 experienced recurrence or the stock would be $1USD, and we would of heard about it already. Therefore unless some of the remaining patients have no recurrence there won't be a Ph2 unless another entity is willing to sponsor us. IMO maybe best to go after one of the other indications in a Ph1. Something where more definitive results can be demonstrated. Don't misunderstand me. I think the results to date for this Ph1 have been stellar, certainly much better than removing some ones bladder. Tld1433 2 or 3 times a year seems preferable to eventual bladder removal. It's just that so far the market thinks otherwise given the 22 cent share price.
Mickey2 wrote: Roger sleeping at the switch?